Kissei Pharmaceutical Co., Ltd.

TSE:4547 Stock Report

Market Cap: JP¥143.9b

Kissei Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mutsuo Kanzawa

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure42.1yrs
CEO ownership3.5%
Management average tenure4.1yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Jul 11
Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

May 21
Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

May 09
Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Mar 27
Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Mar 13
Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

Feb 27
Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

CEO

Mutsuo Kanzawa (75 yo)

42.1yrs

Tenure

Mr. Mutsuo Kanzawa is Chief Executive Officer of Kissei Pharmaceutical Co. Ltd and served as its President since June 1992. Mr. Kanzawa has been the Chairman of Kissei Pharmaceutical Co. Ltd. since June 20...


Leadership Team

NamePositionTenureCompensationOwnership
Mutsuo Kanzawa
Chairman & CEOno datano data3.49%
¥ 5.0b
Yasuo Takehana
President2.1yrsno data0.034%
¥ 48.8m
Takahide Kitahara
GM of Financial Management Department12.1yrsno data0.018%
¥ 26.0m
Yoshio Furihata
Senior Advisor & Director14.1yrsno data0.027%
¥ 39.1m
Keiji Fukushima
Executive VP & Director12.1yrsno data0.023%
¥ 32.5m
Tetsu Takayama
Executive MD & Director4.1yrsno data0.032%
¥ 45.6m
Hiroshi Noake
GM of Pharmaceutical Sales Headquarters & Director2.1yrsno data0.0023%
¥ 3.3m
Keiji Miyazawa
GM of Research Division & Director2.1yrsno data0.0023%
¥ 3.3m

4.1yrs

Average Tenure

62.5yo

Average Age

Experienced Management: 4547's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mutsuo Kanzawa
Chairman & CEO42.1yrsno data3.49%
¥ 5.0b
Yasuo Takehana
President12.5yrsno data0.034%
¥ 48.8m
Takahide Kitahara
GM of Financial Management Department6.1yrsno data0.018%
¥ 26.0m
Yoshio Furihata
Senior Advisor & Director16.1yrsno data0.027%
¥ 39.1m
Keiji Fukushima
Executive VP & Director12.1yrsno data0.023%
¥ 32.5m
Tetsu Takayama
Executive MD & Director10.1yrsno data0.032%
¥ 45.6m
Hiroshi Noake
GM of Pharmaceutical Sales Headquarters & Director2.1yrsno data0.0023%
¥ 3.3m
Keiji Miyazawa
GM of Research Division & Director2.1yrsno data0.0023%
¥ 3.3m
Shigetaka Shimizu
Independent Outside Director10.1yrsno data0.0068%
¥ 9.8m
Sayuri Uchikawa
Independent Outside Director4.1yrsno data0.0023%
¥ 3.3m
Minoru Nomura
Independent Outside Director8.1yrsno data0.0091%
¥ 13.0m
Yoshinori Otsuki
Independent Outside Director2.1yrsno datano data

9.1yrs

Average Tenure

64yo

Average Age

Experienced Board: 4547's board of directors are considered experienced (9.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.